The Sequoia Capital China Intelligent Healthcare Genomics Incubator is intended to create a startup ecosystem in China to help firms develop breakthrough applications in genomics. The companies hope to replicate the success that the Illumina Accelerator project has had in fostering venture-backed startup firms in the U.S. and U.K.

The incubator will have two six-month funding cycles per year and will give startup firms access to investment and business guidance from Sequoia Capital China. They will also gain access to Illumina sequencing systems and reagents, as well as the company's genomics expertise, and its fully operational lab space in Shanghai.

The incubator's first funding cycle will begin in fall 2021.

Emedgene, Illumina partner on rare disease analysis
Emedgene and Illumina have partnered to interpret genomic data for rare diseases.

Illumina's Q2 revenue drops 25%
Illumina's revenue dropped 25% due to the impact of the COVID-19 pandemic on the company's business in the second quarter. The company's net income also...

Illumina launches affordable sequencing kit for labs
Illumina has launched its NovaSeq 6000 v1.5 reagent kit, intended to make genome sequencing more accessible and affordable for labs of all sizes with...

Illumina introduces sequencing software for rare genetic diseases
Illumina has launched software that facilitates whole genome sequencing for rapid identification of rare genetic diseases.

Illumina Accelerator announces new genomics startups
Illumina has chosen seven companies to join the first global cohort of Illumina Accelerator, its startup incubator that partners with entrepreneurs to...